Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis

Healed Erosive Esophagitis Clinical Trial

Official title:
A Phase 3, Double-blind, Randomized, Active-controlled Study to Evaluate the Safety and Efficacy of Tegoprazan as Maintenance Therapy in Patients With Healed Erosive Esophagitis

Status Completed

Clinical Trial Summary

This study is designed to confirm the non-inferiority of Tegoprazan 25mg, compared to Lansoprazole 15mg as maintenance therapy in patients with healed erosive esophagitis confirmed by endoscopy following oral administration once daily(QD) for 6 months.

Clinical Trial Description

This is a double blind, randomized, active-controlled, phase 3 study. Subjects will be randomly assigned to one of the two treatment groups (tegoprazan 25mg, lansoprazole 15mg). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04022096
Study type	Interventional
Source	HK inno.N Corporation
Contact
Status	Completed
Phase	Phase 3
Start date	June 18, 2019
Completion date	June 23, 2021

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04341428` - Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis	Phase 3